The Claim
Pharmacological or adipocyte-specific genetic inhibition of adipose triglyceride lipase (ATGL)-mediated white adipose tissue lipolysis abolishes the increases in FGF21, ketogenesis, brown fat activation, and weight loss induced by G49 in obese mice.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In obese mice, blocking the breakdown of fat in white fat tissue prevents G49 from triggering increased production of FGF21, ketone bodies, activation of brown fat, and weight loss.
See the scientific wording
White adipose tissue lipolysis, mediated by adipose triglyceride lipase (ATGL), is essential for G49-induced metabolic rewiring in obese mice, as pharmacological or adipocyte-specific genetic inhibition of lipolysis abolishes the subsequent increases in FGF21, ketogenesis, brown fat activation, and weight loss.
G49 tells fat cells to break down stored fat into fatty acids. These fatty acids travel to the liver, which uses them to make ketones and a hormone called FGF21. FGF21 and ketones then signal brown fat to burn energy as heat, and also help white fat turn into a more energy-burning type. This whole process burns more calories and leads to weight loss. If fat cells can't break down their stored fat, none of this happens.
What the research says
1 studyG49 is a drug that makes fat cells release stored fat, which then tells the body to burn more energy and lose weight. If you stop fat cells from releasing that fat, G49 doesn’t work — and the study shows exactly that.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.